Metropolis Healthcare (METROPOLIS) Q2 25/26 earnings summary

Executive summary

• Achieved 23% year-over-year group revenue growth for Q2 and H1 FY2026, with organic revenue up 12% and margin expansion in line with guidance.

• Preventive health check-ups, specialty segments (including TruHealth and genomics), and digital/AI initiatives were key growth drivers.

• Integration of recent acquisitions progressing as planned, with focus on operational efficiency and synergy realization in year one, and revenue scaling in year two.

• Continued network expansion, now present in approximately 750 towns, with significant growth in Tier III cities.

• Approved unaudited standalone and consolidated financial results for Q2 and H1 FY2026, with statutory auditors issuing unmodified review reports.

Financial highlights

• Q2FY26 Group revenue rose 23% YoY to INR 429 Cr; EBITDA up 19% YoY to INR 109 Cr; PAT up 13% YoY to INR 53 Cr.

• H1FY26 Group revenue up 23% YoY to INR 815 Cr; EBITDA up 17% YoY to INR 198 Cr; PAT up 16% YoY to INR 98 Cr.

• Organic EBITDA margin reached 26.8%, up 60 bps YoY and 210 bps sequentially; group EBITDA margin at 25.4%.

• Standalone revenue from operations for Q2 FY26 was ₹35,571.32 lakhs, consolidated revenue was ₹42,919.14 lakhs; standalone net profit was ₹4,663.28 lakhs, consolidated net profit was ₹5,289.01 lakhs.

• Board approved a 200% dividend (INR 4 per share), with record date set for 11 November 2025.

Outlook and guidance

• Organic business expected to deliver 70-100 bps margin improvement over last year (24.3%), with group margin diluted by 1-1.2% due to Core Diagnostics.

• Top-line and volume growth guidance for the year maintained; double-digit volume growth (10-11%) expected for the rest of the year.

• Targeting mid-teen revenue CAGR from FY23 to FY26 and a return to pre-COVID margin profiles.

• No price hikes planned for the remainder of the financial year.

• No new acquisitions planned in the next 6-9 months; focus remains on organic growth and integration.